Filgotinib Induces and Maintains Ulcerative Colitis Remission

Filgotinib induced and maintained clinical remission among patients with moderate to severe ulcerative colitis who had not responded to other therapies in a phase 2b and 3 trial published in The Lancet. The oral Janus kinase 1 preferential inhibitor has been previously evaluated in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Source: JAMA - Category: General Medicine Source Type: research